Overview

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Biosciences Japan GK